Ruiyuan Tian
Yong Li- 1Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, China
- 2Department of Hepatobiliary Diseases, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
Metabolic-Associated Fatty Liver Disease (MAFLD) is the most common cause of chronic liver disease and also a major contributor to liver disease-related complications and mortality. It is closely associated with cardiovascular disease (CVD), stroke, type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and non-liver tumors, and has become a significant global public health issue. In recent years, studies have respectively revealed the relationships between the cGAS/STING and STING/NF-κB signaling pathways and MAFLD. Although, in addition to cyclic GMP-AMP synthase (cGAS), various other DNA sensors can also recognize DNA molecules and activate stimulator of interferon genes (STING), their localization response capability and hepatocyte targeting are relatively weak, and most of them only function in specific cell types or physiological states. As a key innate immune mediator, cGAS is the core molecule that activates the classical STING pathway. Therefore, the cGAS/STING/NF-κB signaling pathway may form an important pathological chain of “DNA stress - inflammation - metabolic abnormality” in MAFLD. Consequently, it is necessary to explore the mechanism of action and research progress of the cGAS/STING/NF-κB signaling pathway in MAFLD, which provides new insights for the mechanism research and treatment of MAFLD.
1 Introduction
MAFLD is a metabolic disorder-related liver disease closely associated with insulin resistance (IR) and overnutrition in genetically susceptible individuals. It encompasses non-alcoholic fatty liver disease (NAFLD), mixed fatty liver disease (FLD) with coexisting etiologies, and may occur in patients with other liver diseases such as chronic hepatitis B or autoimmune liver disease. Epidemiological studies indicate that with the prevalence of metabolic disorders like obesity and diabetes, the global prevalence of MAFLD has been increasing annually, establishing it as one of the most common liver diseases worldwide. Research has shown that the burden of non-alcoholic fatty liver disease is rapidly escalating globally (1). The diagnosis of MAFLD requires at least one metabolic risk factor, such as obesity, T2DM, hypertension, or dyslipidemia (2, 3), with over 95% of NAFLD patients meeting the diagnostic criteria for MAFLD (4). Currently, MAFLD has a global prevalence of approximately 38% (5), with a prevalence of 50.7% (95% CI, 46.9–54.4) in overweight or obese adults. Men exhibit a higher prevalence of MAFLD (59.0%; 95% CI, 52.0–65.6) compared to women (47.5%; 95% CI, 40.7–54.5) (6). The global prevalence of NAFLD/MAFLD in T2DM patients is 65.33% (95% CI, 62.35%–68.18%) (7, 8), while the estimated global prevalence in children and adolescents is 7.4% (9). Notably, MAFLD is not confined to obese or overweight individuals; individuals with normal body weight are also at risk (10–12). The incidence of NAFLD in non-obese or lean populations is 24.6 (95% CI 13.4–39.2) per 1000 person-years (13). In multi-ethnic populations in the United States, the prevalence of non-obese NAFLD is 9.6%, with one-third comprising elderly individuals, men, and others, and a higher mortality rate compared to obese NAFLD (14). Lean NAFLD is defined as “metabolically unhealthy normal weight,” characterized by reduced subcutaneous fat and ectopic hepatic fat deposition (15).
MAFLD is associated with a variety of systemic diseases. Owing to its close association with insulin resistance—which constitutes a major cardiovascular risk factor in non-diabetic patients (16)—studies have demonstrated (17–20) that individuals with MAFLD exhibit a higher cumulative incidence and risk of cardiovascular diseases (including hypertension and atherosclerosis) compared to those without MAFLD (21, 22), with an associated hazard ratio (HR) of 1.38 (95% confidence interval: 1.37–1.39); the HR for stroke is 1.55 (95% confidence interval: 1.37–1.73).The prevalence of CKD related to non-alcoholic fatty liver disease ranges from 20% to 55%, and its severity is correlated with CKD staging (23–25). Furthermore, the risk of developing CKD in patients with MAFLD/MASLD increases with the severity of fatty liver. Even after disease remission, patients with a history of moderate-to-severe fatty liver still have a relatively high risk of CKD. In addition, the progression from simple steatosis to non-alcoholic steatohepatitis (NASH) is associated with an increased incidence of liver cirrhosis and hepatocellular carcinoma (26), as well as a higher overall mortality rate (27). This underscores the multifaceted impacts of MAFLD and its potential threat to human health.
Lean NAFLD exhibits histological phenotypes similar to those in obese patients, carrying a greater risk of severe liver disease progression, with higher prevalence of diabetes, advanced fibrosis, and cirrhosis. It is characterized by impaired glucose metabolism, adipose tissue dysfunction, and a high proportion of lobular inflammation (28, 29). Consequently, lean NAFLD is associated with a higher degree of visceral adipose tissue and adipose tissue dysfunction, with the severity of histological injury independent of body mass index (30).
As a prevalent chronic liver disease worldwide, MAFLD imposes a significant public health burden due to its potential complications, and no effective treatments currently exist (31). Its pathogenesis and progression are regulated by factors such as hepatic lipid accumulation, oxidative stress, insulin resistance, immune and metabolic dysfunction, and apoptosis (32–34). Epidemiological features reflect its complexity, closely intertwined with immune, inflammatory, and metabolic dysfunction, involving interactions across multiple biological processes and signaling pathways. The cGAS/STING pathway has been extensively studied in autophagy, infection, metabolism, cancer, inflammation, and aging (35), but the mechanisms underlying cGAS/STING/NF-κB interactions in MAFLD pathogenesis remain underexplored. This pathway may play a complex role in MAFLD, making it crucial to investigate its mechanisms to identify novel therapeutic targets.
2 The cGAS/STING/NF-κB signaling pathway and MAFLD
The immune system is intimately linked to metabolic regulation across all animal species. Beyond its primary role in innate defense against pathogen infections, research has revealed that the cGAS-stimulated pathway plays a pivotal role in metabolic processes. The cGAS-STING axis serves as a central innate immune defense mechanism against viral infections, primarily driving the production of type I interferons. This pathway is not only critical for antiviral responses but also influences bacterial infection defenses, immune-mediated diseases, and inflammatory processes (36, 37). Immune responses and metabolic homeostasis are deeply intertwined, with chronic low-grade inflammation known to promote the development of metabolic disorders (38–40). Over the past decade, growing evidence has highlighted the significance of innate immunity in the pathogenesis of hepatic steatosis and NAFLD (41).
Existing studies have shown that in addition to the classical pathway, a variety of DNA sensors can also activate the STING signal, including IFI16, DDX41, DAI, MRE11, and DNA-PK. These sensors together form a multi-dimensional regulatory network for STING activation through methods such as directly recognizing DNA molecules, regulating cGAS activity, or mediating non-classical signaling pathways. Among them, cGAS, as a core molecule, dominates pathway activation, while IFI16, DDX41, DAI, MRE11, and DNA-PK play supplementary regulatory roles in specific cell types or physiological conditions. The dynamic balance of the aforementioned mechanisms is of great significance in tumorigenesis, infection response, and the progression of autoimmune diseases.
Specifically, interferon-inducible factor 16 (IFI16) is crucial for maintaining STING protein levels and the immune response after activation of the IFN-γ response pathway in metastatic melanoma (42); cell cycle inhibitors can mediate anti-tumor immune responses in liver cancer by activating the hypoxia-induced DDX41/STING pathway (43); DAI (also known as DLM-1/ZBP1), as a cytoplasmic DNA sensor, is a key activator of innate immune responses (44), although studies have found that mice with DAI gene knockout can still express large amounts of type I interferons under stimulation with type B DNA (45); MRE11 can participate in pathway regulation by releasing cGAS from nucleosome sequestration during tumorigenesis (46), and its dependent instability in mitochondrial DNA fork protection can activate the cGAS immune signaling pathway (47); meanwhile, as a DNA damage sensor, MRE11 can also recognize cytoplasmic double-stranded DNA (dsDNA) and induce type I interferons by regulating STING transport (48); DNA-PK, as a DNA sensor for IRF-3-dependent innate immunity (49), can activate STING in DNA damage response through a cGAS-independent pathway (50).
Studies have shown that high glucose levels, intracellular lipid accumulation in hepatocytes, activation of dsDNA and cyclic dinucleotides (CDNs), endoplasmic reticulum stress (ER stress), mitochondrial stress, as well as energy imbalance in metabolic cells and immune cells, can activate the cGAS-STING pathway. STING is relocalized from the endoplasmic reticulum to the endoplasmic reticulum-Golgi intermediate compartment, leading to the palmitoylation of cysteine residues at positions 88 and 91 in the N-terminal domain of STING in the Golgi apparatus, thereby activating TANK-binding kinase 1 (TBK1). TBK1 phosphorylates the serine and threonine residues of STING, and the phosphorylated STING has increased affinity for IRFs, thus recruiting interferon regulatory factor 3 (IRF3) for TBK1-dependent phosphorylation and activation. The activated IRF3 dimers translocate to the nucleus, inducing the expression of type I interferons (IFNs) and various immunoregulatory factors, thereby triggering pro-inflammatory responses and metabolic disorders (51). Pathological overactivation of this pathway is closely linked to metabolic conditions such as obesity, NAFLD, insulin resistance, and cardiovascular diseases (CVDs). Research has identified interactions between cGAS-STING and other signaling pathways—including nuclear factor-κB (NF-κB), Jun N-terminal kinase (JNK), AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), lipophagy, pyroptosis, and the insulin signaling cascade—as key mechanisms through which cGAS-STING modulates inflammation and metabolic homeostasis (38, 39). (Figure 1).
Figure 1. cGAS-STING signaling pathway. When bacteria and viruses invade, or high sugar is ingested, or lipid accumulation occurs in liver cells, or when cells are damaged (including damaged mtDNA), DNA fragments accumulate in the cytoplasm. The cGAS recognizes cytoplasmic long DNA fragments and catalyzes the synthesis of 2 ′ 3 ′ - cyclic GMP cAMP (cGAMP). CGAMP binds to the dimer of STING located on the endoplasmic reticulum (ER) membrane, causing oligomerization of STING. This leads to the incorporation of STING into the shell protein complex II (COPII) vesicles, initiating the transport of STING from the ER to the Golgi apparatus and the ER Golgi apparatus. STING activates serine/TBK1, which in turn phosphorylates IRF3. Phosphorylated IRF3 then activates the expression of IFN-I in the nucleus. The activation of STING also leads to the activation of NF-κB and the formation of autophagosomes through non classical mechanisms. NF-κB activation promotes the expression of pro-inflammatory cytokines, ultimately leading to the degradation of STING in autophagosomes and lysosomes.
In MAFLD, intracellular environmental changes driven by factors like fat accumulation lead to abnormal DNA release and recognition (52). These changes induce chromatin modifications, exposing previously sequestered DNA and activating cGAS. cGAS catalyzes the synthesis of the second messenger cGAMP, which is transported to STING on the endoplasmic reticulum membrane (53), thereby initiating the cGAS-STING innate immune pathway. Activated STING triggers NF-κB, causing inflammatory responses and metabolic disorders, thereby promoting the progression of MAFLD (54). Recent studies have shown that the NLRP3 inflammasome can be directly activated by cGAMP or STING, which can enhance hepatocyte pyroptosis, inflammation, and fibrosis. This may be an important mechanism that exacerbates MAFLD fibrosis (55, 56).
2.1 cGAS - STING pathway
2.1.1 cGAS-STING pathway and macrophages in liver inflammation and lipid accumulation
Tightly associated with nucleosomes, it acts as a mediator regulating innate immunity, capable of recognizing DNA abnormally present in the cytoplasm and can be activated by double-stranded dsDNA from multiple sources (58, 59). Under physiological conditions, cGAS remains in an inactive state. Under pathological conditions, once activated, cGAS catalyzes the synthesis of the second messenger cGAMP. This activates stimulator of STING, inducing its conformational change and translocation from the endoplasmic reticulum to the Golgi apparatus, which then recruits and activates downstream signaling molecules to transmit immune responses (60).
Liver macrophages exhibit heterogeneity in their origins, including Kupffer cells derived from the yolk sac/fetal liver and populations derived from bone marrow monocytes. STING is a transmembrane protein primarily localized in the endoplasmic reticulum; it is mainly expressed in liver macrophages, including CCR2+, S100A9+, Kupffer cells, and CD163+ cells (61, 62). Conformational changes in STING drive the production of factors that promote lipid accumulation in hepatocytes and pro-inflammatory responses, thereby contributing to hepatic steatosis, inflammation, and fibrosis (63).
Therefore, in recent years, the role of the cGAS-STING pathway in alcoholic/non-alcoholic steatohepatitis has received widespread attention (58). Non-alcoholic steatohepatitis is considered to be associated with sterile inflammation mediated by innate immunity; in the pathogenesis of NAFLD (non-alcoholic fatty liver disease), the involvement of cGAS-STING signaling via DNA-induced type I interferon responses has become increasingly prominent (64, 65). Endoplasmic reticulum stress in MAFLD (metabolic-associated fatty liver disease) activates the unfolded protein response (UPR), upregulates the expression of STING, mediates immune and metabolic responses, and exacerbates hepatic inflammation and cellular damage (66, 67). Excessive activation of cGAS-STING can also aggravate chronic inflammation, leading to metabolic dysfunction, aging, and conditions such as obesity and neurodegenerative diseases (68).
Recent studies have emphasized that, beyond the traditional M1/M2 model, macrophages also exhibit a series of activation states, which influence the diversity of their functions (69). Under cGAS-STING activation, macrophages differentiate into pro-inflammatory M1 phenotypes, secreting tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and Interleukin-6(IL-6) to induce hepatic inflammation and fat deposition, accelerating NAFLD progression (68). cGAS can also polarize macrophages to an M1 phenotype via the mTORC1 pathway, mediating inflammatory responses (70). Importantly, macrophage - mediated insulin resistance exists independently of inflammation and appears before the onset of inflammation (71). Therefore, in the early stage of a high - fat diet without inflammation, depleting liver macrophages can improve insulin sensitivity (72, 73). Pro-inflammatory cytokines further inhibit hepatocyte lipid metabolism genes via the PPAR-α pathway, promoting steatosis (12, 74). In lean NAFLD mice, abnormal elevation of the macrophage cholesterol sensor SCAP drives STING translocation to the Golgi apparatus, recruiting TBK1 for phosphorylation, which induces metabolic inflammation, promotes lipolysis, and increases hepatic lipid deposition (75).
STING activation in lipid metabolism pathways can exacerbate fat accumulation (76). Excessive hepatic lipid storage generates lipotoxins, inducing mitochondrial dysfunction, endoplasmic reticulum stress, and reactive oxygen species (ROS) overproduction (64, 65). Lipotoxicity further triggers the release of mitochondrial DNA, lipid antigens, and adipokines, reactivating cGAS-STING to form a self-reinforcing cycle of inflammation and metabolic dysregulation.
2.1.2 cGAS-STING pathway is activated by endoplasmic reticulum/mitochondrial stress
This chronic inflammation caused by glucotoxicity and resulting in IR is also common to NAFLD and T2DM. Hyperglycemia causes abnormal intracellular protein glycosylation, leading to misfolded or unfolded proteins accumulating in the endoplasmic reticulum and triggering the unfolded protein response (78). Some studies have found that oxidative stress induced by hyperglycemia promotes mitochondrial dysfunction and the release of mitochondrial DNA, which subsequently activates the cGAS-STING pathway as well as cGAS-STING-dependent IRF3 (79). It also induces the polarization of macrophages into a pro-inflammatory phenotype and the release of pro-inflammatory cytokines (80). A large number of studies have shown that in mammals, endoplasmic reticulum stress is closely related to the regulation of nutrient sensing and glycolipid metabolism. Endoplasmic reticulum stress affects the regulatory mechanisms of metabolic pathways in different tissues and organs such as the liver, adipose tissue, islets, and hypothalamus, thus playing an important role in the occurrence and development of glycolipid metabolism disorders.
2.1.3 High-fat diet, gut dysbiosis, and cGAS activation in MAFLD
Increasing evidence highlights a close association between the gut microbiota and NAFLD progression (82), with microbial imbalance identified as a key determinant in MAFLD and metabolic syndrome (83). Diet acts as a powerful modulator of gut microbial composition and mucosal immune responses (84, 85).
High-energy diets and overnutrition are major factors altering fat metabolism, systemic inflammation, and gut microbiota profiles (86). A high-fat diet can trigger cGAS-STING-IRF3-mediated inflammatory responses (87), while diets rich in animal protein promote anti-inflammatory macrophage activity, worsen intestinal inflammatory damage, and rapidly reshape gut microbial communities (88). Consuming a high-sugar diet (HSD) impairs the intestinal mucosal barrier and modulates immune responses (89); excessive dietary monosaccharides reduce microbial diversity and deplete short-chain fatty acids (SCFAs), which possess immunomodulatory properties and influence colonic regulatory T cell absorption and macrophage antibacterial activity (90). SCFA depletion alters both intestinal bacterial and fungal microbiota composition. Gut microbiota-derived endotoxins like lipopolysaccharide (LPS) enter the liver via the portal vein, activating hepatic Toll-like receptor 4 (TLR4). In LPS-induced inflammation, cGAS is upregulated through the TLR4 pathway (91), subsequently activating the STING-NF-κB signaling cascade and inducing hepatic inflammatory responses.
2.1.4 cGAS-STING pathway promotes hepatic fibrosis and hepatic sinusoidal microthrombosis
Activation of this signaling cascade triggers the release of pro-inflammatory factors, which not only recruit immune cell infiltration but also amplify local inflammatory responses. When hepatic sinusoidal endothelial cells are damaged or inflamed, conditions conducive to microthrombus formation arise, accompanied by endothelial-mesenchymal transition (EndMT), directly contributing to microthrombus development (93).
Upregulated cGAS-STING signaling initiates signals that drive the activation of hepatic stellate cells (HSC). The resulting cytokines and chemokines act on HSC, inducing the expression of fibrosis-related genes like α-smooth muscle actin (α-SMA) and collagen-I, thereby exacerbating liver fibrosis and intrahepatic inflammation. Additionally, this pathway promotes the upregulation of differentially expressed genes (DEG) in liver tissue, inducing phenotypic changes in hepatic sinusoidal endothelial cells that enhance inflammatory responses and release pro-coagulant factors, facilitating microthrombus formation. These phenotypic alterations lead to reduced or absent fenestrae, increased resistance to sinusoidal blood flow, and impaired circulation—mechanisms critical for both thrombus formation and the development of portal hypertension (94, 95).
2.1.5 The cGAS-STING signaling pathway and renal injury
The cGAS-STING signaling pathway plays a key role not only in innate immune surveillance but also in additional biological processes, including kidney diseases (96, 97). MAFLD serves as a significant risk factor for CKD (98, 99). Recent in-depth investigations into the innate immune functions of this pathway have revealed emerging evidence that it may possess roles beyond traditional immune surveillance. Consistent with this, dysregulation of cGAS-STING signaling in adipocytes, hepatocytes, and renal proximal tubular epithelial cells has been linked to metabolic dysfunction, energy balance disorders, and kidney pathologies (100, 101).
As a highly metabolic organ rich in mitochondria, the kidney relies on mitochondrial integrity; impaired mitochondrial function and tubular inflammation are established pathogenic mechanisms driving acute kidney injury (AKI) and subsequent CKD progression. Some studies have confirmed (102) that disulfide bond A oxidoreductase-like protein (DsbA-L) mitigates mitochondrial stress-induced mtDNA release and cGAS-STING pathway activation in adipose tissue, thereby alleviating high-glucose-induced renal tubular damage and preventing ectopic fat accumulation in diabetic nephropathy and fat-related kidney injury (103, 104). Additionally, the cGAS-cGAMP-STING axis has been shown to contribute to the development of AKI, immune-related kidney diseases, and renal tumors by recognizing self-DNA and initiating sterile inflammatory responses (105). (Figure 2).
Figure 2. The cGAS stimulation pathways in metabolism and kidney disease. In metabolic tissues such as adipose tissue and liver, high-fat and high sugar diet or alcohol induces activation of the CGAS stimulation pathway. In adipose tissue, the activated CGAS spike pathway promotes inflammation, inhibits thermogenesis, leading to obesity and insulin resistance in the body. In the liver, CGAS nail activation is associated with the development of ALD, NAF, and Nash. In the kidneys, the activated CGAS nail pathway contributes to AKI, MAFLD, and tumors.
2.2 The STING/NF-κB pathway
The STING and NF-κB signaling pathways are crucial in the pathogenesis of MAFLD (106, 107). Recent studies have shown that STING triggers downstream signals and activates the NF-κB pathway through non-canonical mechanisms, which exacerbates inflammatory responses and promotes hepatic lipid accumulation and fibrosis (108, 109).
New evidence reveals that the UPR and NF-κB pathways converge in the nucleus through ten key transcription factors (TFs): activating transcription factor 4(ATF4), ATF3, CCAAT/enhancer-binding protein (CEBP) homologous protein (CHOP), X-box binding protein (XBP) 1, ATF6α, and five NF-κB subunits. These TFs collectively bind to numerous genomic regions (enhancers and promoters), coordinating the transcriptional activation or repression of hundreds of genes. This genomic regulation determines the balance between metabolic and inflammatory phenotypes, as well as the outcomes of apoptosis, autophagy, damaged cell repair, and cell survival (110). (Figure 3).
Figure 3. Integration of UPR and NF-κB signaling at chromatin. UPR and NF-κB pathways converge within the nucleus through ten major transcription factors. The combinatorial occupancy of numerous genomic regions (enhancers and promoters) coordinates the transcriptional activation or repression of hundreds of genes that collectively determine the balance between metabolic and inflammatory phenotypes and the extent of apoptosis and autophagy or repair of cell damage and survival.
NF-κB plays a pivotal role in regulating metabolic hormones (109), influencing major pathways such as glycation, triglyceride homeostasis, and lipogenesis. This transcription factor modulates the expression of key hormones like insulin and glucagon, which are essential for maintaining glucose levels and lipid metabolism (111). However, dysregulated NF-κB activation can disrupt hormonal balance, affecting adipocyte function and insulin signaling to impair lipid metabolism and energy homeostasis. Experimental models (112) demonstrate that mild hepatic NF-κB activation via IKβ regulation increases triglyceride levels and lipogenesis, while disrupting hypothalamic insulin and leptin signaling, leading to IR, energy imbalance, and obesity (113). These effects underlie the pathway’s role in triggering metabolic disorders and associated diseases (114, 115).
Chronic inflammation and fibrosis are central to metabolic-associated fatty liver pathogenesis, driving disease progression through inflammatory mechanisms that permeate all stages of MAFLD (116). NF-κB activation promotes the production of pro-inflammatory factors like TNF-α and IL-1β, amplifying the inflammatory cascade (117). This exacerbates hepatic metabolic dysfunction, induces hepatocyte damage, and accelerates the transition from MAFLD to non-alcoholic steatohepatitis (NASH) and fibrosis. Meanwhile, activated hepatic stellate cells (HSCs) transdifferentiate into myofibroblasts. These cells secrete collagen and extracellular matrix components, ultimately leading to hepatic fibrosis (118). Established fibrosis further impairs hepatic function and may progress to cirrhosis.
In summary, cGAS detects abnormal or mislocalized dsDNA, initiating activation and production of the second messenger cGAMP (57, 58). Binding to STING triggers its translocation to the Golgi apparatus, where TBK1 is activated, phosphorylating both STING and IRF3 (59). Phosphorylated IRF3 translocates to the nucleus, initiating type I interferon (IFN-I) production and downstream IFN-stimulated gene expression. Simultaneously, STING engages the IκB kinase (IKK) complex to phosphorylate the NF-κB inhibitor IκBα, facilitating NF-κB nuclear translocation and enhancing the transcription of pro-inflammatory cytokines (108, 109). This coordinated signaling amplifies both innate immune and inflammatory responses, driving MAFLD progression. (Figure 4).
Figure 4. Molecular mechanism of cGAS-STING- NF-κB signaling. cGAS senses aberrant or mislocalized dsDNA to generate cGAMP, binding to STING to induce the relocation of STING to Golgi apparatus and trigger activation of TBK1 to result in phosphorylation of both STING and IRF3 transcription factor. In addition, IFN-I is initiated upon translocation of IRF3 into the nucleus, which subsequently induces various IFN-stimulated genes. At the same time, STING has ability to enlist IKK, which then triggers phosphorylation of the NF-κB inhibitor, IkBa, speeding up movement of NF-κB into the nucleus, which in turn enhances the production of certain inflammatory cytokines.
2.3 Feedback of the cGAS/STING/NF-κB signaling pathway
In MAFLD, the interplay between cGAS, STING, and NF-κB creates a vicious cycle. Obesity, inflammation, and hepatic fat accumulation trigger cGAS activation, which subsequently activates STING. Activated STING then initiates NF-κB signaling, driving a robust inflammatory response that can further amplify STING activation.
This crosstalk forms a feedback loop critical for liver injury and MAFLD progression (119). (Figure 5).
Figure 5. NF-κB is activated into the nucleus, regulates the release of inflammatory factors such as TNF-α and IL-1β, and causes changes in DNA conformation, thus initiating the innate immune response. NF-κB can also induce nucleosome remodeling, in which cGAS is released from nucleosome isolation, allowing it to function in response to dsDNA, thereby activating the CGAS-STING signaling pathway.
Upon activation, NF-κB translocates to the nucleus, where it regulates the expression of inflammation-related genes and triggers inflammatory responses. This process is accompanied by DNA conformational changes that initiate canonical innate immune responses (120). During Toll-like receptor 4 signaling, NF-κB coordinates inducible nucleosome remodeling, activating enhancers and promoters within open chromatin regions (121). By remodeling nucleosomes, cGAS is released from nucleosomal sequestration, enabling its interaction with cytosolic dsDNA to activate the cGAS-STING pathway (46). Open chromatin structures also enhance cGAS-DNA interactions, facilitating pathway activation (122, 123).
Research shows that STING relies on microtubules for intracellular transport. NF-κB pathway activation induces microtubule disassembly, inhibiting STING transport to lysosomes for degradation and sustaining prolonged STING activation. This synergy between NF-κB and STING amplifies interferon responses. Additionally, gain-of-function STING mutations disrupt microtubule binding, causing abnormal STING trafficking and ligand-independent autoactivation. Thus, NF-κB enhances STING signaling by regulating microtubule-mediated transport, perpetuating inflammatory cascades (124). (Figure 6).
Figure 6. Activation of the NF-κB pathway enhances STING-mediated immune response. NF-κB activation prolongs and increases STING signaling by inhibiting microtubule-mediated transport of STING from austenite to lysosome, thereby blocking STING degradation. This enhances STING-mediated interferon response and host antiviral defense.
The dysregulated cyclic activation of this signaling pathway may promote further liver inflammation and cellular damage, leading to progressive exacerbation of hepatic inflammation in MAFLD patients and potentially driving the development of liver fibrosis and even hepatocellular carcinoma (125). Studies also indicate that cGAS/STING/NF-κB pathway activation induces inflammation and IR (102), with IR representing a central driver of MAFLD pathogenesis that arises from interactions across multiple signaling networks (38, 64).
In summary, within metabolic-associated fatty liver diseases, the cGAS/STING and NF-κB pathways exhibit intricate crosstalk: cGAS/STING activation triggers NF-κB signaling, driving the production of pro-inflammatory cytokines such as TNF-α and IL-6. These cytokines intensify hepatic inflammation, disrupt glucose and lipid metabolism, induce hepatocyte fat accumulation and IR, and collectively accelerate fatty liver progression.
3 Treatment strategies for intervening in the cGAS/STING/NF-κB signaling pathway in MAFLD
Given the critical role of the cGAS/STING/NF-κB signaling pathway in MAFLD, developing drugs targeting this axis offers promise as a novel therapeutic strategy. Current treatment approaches focusing on this pathway primarily include the following aspects:
3.1 Small-molecule inhibitors
Blocking specific steps in the cGAS-STING cascade may alleviate inflammation. Targeted small-molecule inhibitors of cGAS or STING effectively dampen inflammatory responses (59). These agents counteract MAFLD progression by reducing hepatic inflammation and damage—for example, by blocking cGAS-DNA binding or interfering with STING downstream signaling.
DNA Release Regulation: PPARα may modulate cGAS-STING transduction via mitochondrial DNA (mtDNA) release, suggesting PPAR pathway modulation could regulate cGAS activation (126). Tanreqing has been shown to inhibit mtDNA release and STING-mediated signaling in vitro (127).
RU.521 is a potent and selective cGAS inhibitor capable of potently suppressing cGAS-mediated interferon upregulation, thereby inhibiting the onset of inflammation. As a cGAS inhibitor, RU.521 reduces downstream STING-induced IFN and pyroptosis (128).
STING Inhibition: STING-specific inhibitors like C-170 and C-176 block cGAMP binding to STING (129), while H-151 inhibits STING/NF-κB signaling in immune cells (130).Recent studies have shown that the LXR/RXR agonist UAB116, whose known functions include regulating cholesterol metabolism, lipid transport, and immune response, can upregulate TRIM29 (131). As a widely existing ubiquitin E3 ligase, TRIM29 is a key negative regulator of the STING signaling pathway. It can inhibit inflammatory responses and oxidative stress, as well as negatively regulate antiviral immunity by degrading the downstream molecule STING (132, 133).
In addition, TRIM29 can alleviate endoplasmic reticulum stress by regulating the activity of PERK, thereby reducing hepatocyte damage in metabolic-associated fatty liver disease and improving metabolic outcomes. As a core regulatory factor of the UPR, PERK mainly functions to sense endoplasmic reticulum stress and helps cells restore homeostasis by regulating protein synthesis and degradation processes (134, 135).
It should be noted that TRIM29 promotes K48-linked ubiquitination, which can lead to the degradation of NOD-like Receptor Family Pyrin Domain Containing 6(NLRP6) and NOD-like Receptor Family Pyrin Domain Containing 9b (NLRP9b). This degradation reduces the secretion of IFN-λ and IL-18 by intestinal epithelial cells (IECs), impairs the inhibitory effect of NLRP6 on other inflammatory pathways (such as the NF-κB pathway and TLR signaling pathway), and ultimately induces intestinal inflammation (136).
Furthermore, the reduction in IL-18 (an effector protein of NLRP6) disrupts the negative regulation of the intestinal microbiota, allowing TLR4 and TLR9 agonists to enter the portal vein. This leads to increased TNF-α expression in the liver, exacerbates hepatic steatosis and inflammation, and promotes the progression of NAFLD/NASH (137). Therefore, the exploration of drugs that bypass TRIM29 and act on NLRP6—such as pioglitazone, which can upregulate the expression of NLRP6 (138)—is of great significance. The combined action of such drugs with TRIM29 may play a positive role in the comprehensive improvement of MAFLD.
Although current research on directly targeting TRIM29 for MAFLD treatment is still in its early stages, TRIM29 has potential effects by regulating mechanisms such as the STING pathway, immune microenvironment, DNA damage repair, and alleviation of endoplasmic reticulum stress. Its combined use with NLRP6 agonists may provide a new strategy for MAFLD treatment.
Notably, TRIM29 also exhibits a dual function of suppressing or promoting cancer in various types of cancer: it exerts a cancer-promoting effect in cancers such as lung cancer, colon cancer, nasopharyngeal carcinoma, esophageal cancer, and pancreatic cancer, while in liver cancer, it can reverse the resistance to lenvatinib (139–147).
3.2 Anti-inflammatory therapies
Pharmacological interventions targeting inflammation, such as glucocorticoids, downregulate NF-κB activation and reduce pro-inflammatory cytokine production. Clinical studies indicate these drugs can alleviate hepatic inflammation in NASH patients (31, 148).
Signaling Pathway Modulation: Insulin promotes anti-inflammatory macrophage polarization and inhibits NF-κB expression (149, 150), while tofacitinib and aspirin suppress JAK-STAT and NF-κB pathways, respectively, mitigating type 2 diabetes progression (151). Ferulic acid prevents M1 macrophage polarization in diabetes-related inflammation by inhibiting TLR4/IL-6-mediated NF-κB/JAK-STAT signaling (AGE-RAGE interactions) (152).
Metal Ion Regulation: Zinc ion (Zn²+) chelator TPEN inhibits intracellular cGAS activation, highlighting metal ions as potential regulators of cGAS-STING-mediated inflammation (153).
3.3 Nutritional and lifestyle interventions
Dietary adjustments and increased physical activity can partially regulate the cGAS/STING/NF-κB pathway, improving hepatic metabolic status (125, 154). Reducing high-fat intake, for example, decreases cGAS/STING activation and alleviates fatty liver symptoms.
3.4 Pathway dual roles and precision medicine
While the cGAS/STING/NF-κB axis promotes inflammation and metabolic dysfunction in MAFLD, it may exhibit protective effects during infections or immune responses by enhancing pathogen resistance (155). Understanding its context-dependent dual functions is critical for developing targeted therapies. Advances in genomics and proteomics will enable personalized treatment strategies by elucidating interindividual variations in pathway activity (124).
3.5 Novel drug development
Future research is likely to yield more clinical-specific cGAS/STING/NF-κB inhibitors. Combined therapies targeting multiple signaling pathways (such as nanomedicines for regulating cGAS-STING and drugs targeting TRIM29 for treatment) are expected to improve therapeutic efficacy (156).
3.6 Multidisciplinary collaboration
Treating MAFLD requires integrated efforts from endocrinology, gastroenterology, and immunology disciplines (52, 157). Interdisciplinary research will deepen understanding of the pathway’s role in metabolic diseases, accelerating the development of innovative therapeutic strategies.
4 Conclusion
The cGAS/STING/NF-κB signaling pathway plays a crucial role in the pathogenesis and progression of MAFLD. Activation of this pathway not only triggers hepatic inflammatory responses and IR but also regulates lipid metabolism, thereby promoting the development of hepatic fibrosis and cirrhosis. Therefore, targeting the cGAS/STING/NF-κB signaling pathway has become a highly promising novel therapeutic strategy for MAFLD.
However, due to the complexity of the immune regulatory network, the molecular differences and sources of factors (such as hyperglycemia, lipid accumulation, and viruses) that trigger abnormal DNA release have not been fully elucidated. Moreover, there may be differences in regulatory mechanisms across different stages of MAFLD—including simple fatty liver, steatohepatitis, hepatic fibrosis, and cirrhosis—as well as variations in the components of metabolic abnormalities among affected individuals. These aspects require in-depth analysis. In the future, efforts should be made to deepen the exploration of molecular mechanisms such as metabolomics and proteomics, and accurately identify the upstream triggers of cGAS activation. This will provide support for the individualized treatment of MAFLD, facilitate the development of more effective drugs and intervention strategies, and ultimately bring new hope to the clinical management of MAFLD.
Author contributions
RT: Investigation, Writing – original draft. YL: Writing – review & editing, Methodology, Writing – original draft.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. Authors were funded by “Shandong Province Integrated Traditional Chinese and Western Medicine Disease Prevention and Control Project”, Shandong Province (YXH2019ZXY003).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM, et al. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun. (2023) 7:e0251. doi: 10.1097/HC9.0000000000000251, PMID: 37782469
2. Chinese Society of Hepatology, Chinese Medical Associa tion. Guidelines for the Prevention and Treatment of Metabolic-Associated (Non-Alcoholic) Fatty Liver Disease (2024 Version). Chin J Hepatol. (2024) 32:418–34. doi: 10.3760/cma.j.cn501113-20240327-00163, PMID: 38858192
3. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. (2024) 17:374–444. doi: 10.1159/000541386, PMID: 39284304
4. Song SJ, Lai JC, Wong GL, Wong VW, and Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. (2024) 80:e54–6. doi: 10.1016/j.jhep.2023.07.021, PMID: 37541393
5. Wong VW, Ekstedt M, Wong GL, and Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. (2023) 79:842–52. doi: 10.1016/j.jhep.2023.04.036, PMID: 37169151
6. Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. (2022) 20:e573–82. doi: 10.1016/j.cgh.2021.02.030, PMID: 33618024
7. Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. (2024) 22:1999–2010.e8. doi: 10.1016/j.cgh.2024.03.006, PMID: 38521116
8. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. (2019) 71:793–801. doi: 10.1016/j.jhep.2019.06.021, PMID: 31279902
9. Li J, Ha A, Rui F, Zou B, Yang H, Xue Q, et al. Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021. Aliment Pharmacol Ther. (2022) 56:396–406. doi: 10.1111/apt.17096, PMID: 35736008
10. Tang SY, Tan JS, Pang XZ, and Lee GH. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact. World J Gastroenterol. (2023) 29:549–60. doi: 10.3748/wjg.v29.i3.549, PMID: 36688021
11. Méndez-Sánchez N, Brouwer WP, Lammert F, and Yilmaz Y. Metabolic dysfunction associated fatty liver disease in healthy weight individuals. Hepatol Int. (2024) 18(Suppl 2):884–96. doi: 10.1007/s12072-024-10662-w, PMID: 39052203
12. Huang X, Yao Y, Hou X, Wei L, Rao Y, Su Y, et al. Macrophage SCAP contributes to metaflammation and lean NAFLD by activating STING-NF-κB signaling pathway. Cell Mol Gastroenterol Hepatol. (2022) 14:1–26. doi: 10.1016/j.jcmgh.2022.03.006, PMID: 35367665
13. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. (2020) 5:739–52. doi: 10.1016/S2468-1253(20)30077-7, PMID: 32413340
14. Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. (2020) 288:139–51. doi: 10.1111/joim.13069, PMID: 32319718
15. Fan JG, Kim SU, and Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. (2017) 67:862–73. doi: 10.1016/j.jhep.2017.06.003, PMID: 28642059
16. Gutiérrez-Cuevas J, Santos A, and Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: A link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. (2021) 22:11629. doi: 10.3390/ijms222111629, PMID: 34769060
17. Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. (2024) 73:533–40. doi: 10.1136/gutjnl-2023-331003, PMID: 37907259
18. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet. (2005) 366:1640–9. doi: 10.1016/S0140-6736(05)67663-5, PMID: 16271645
19. Gungor N, Thompson T, Sutton-Tyrrell K, Janosky J, and Arslanian S. Early signs of cardiovascular disease in youth with obesity and type 2 diabetes. Diabetes Care. (2005) 28:1219–21. doi: 10.2337/diacare.28.5.1219, PMID: 15855596
20. Akil L and Ahmad HA. Relationships between obesity and cardiovascular diseases in four southern states and Colorado. J Health Care Poor Underserved. (2011) 22:61–72. doi: 10.1353/hpu.2011.0166, PMID: 22102306
21. Csige I, Ujvarosy D, Szabo Z, Lőrincz I, Paragh G, Harangi M, et al. The impact of obesity on the cardiovascular system. J Diabetes Res. (2018) 2018:3407306. doi: 10.1155/2018/3407306, PMID: 30525052
22. Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12 620 736 individuals. Endocr Pract. (2022) 28:667–72. doi: 10.1016/j.eprac.2022.03.016, PMID: 35364328
23. Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, Itoh Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. (2011) 60:735–9. doi: 10.1016/j.metabol.2010.07.022, PMID: 20817213
24. MaChado MV, Gonçalves S, Carepa F, Coutinho J, Costa A, and Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int. (2012) 32:241–8. doi: 10.1111/j.1478-3231.2011.02623, PMID: 22098270
25. Gao J, Li Y, Zhang Y, Zhan X, Tian X, Li J, et al. Severity and remission of metabolic dysfunction-associated fatty/steatotic liver disease with chronic kidney disease occurrence. J Am Heart Assoc. (2024) 13:e032604. doi: 10.1161/JAHA.123.032604, PMID: 38390843
26. Friedman SL, Neuschwander-Tetri BA, Rinella M, and Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. (2018) 24:908–22. doi: 10.1038/s41591-018-0104-9, PMID: 29967350
27. Zarghamravanbakhsh P, Frenkel M, and Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metab Open. (2021) 12:100149. doi: 10.1016/j.metop.2021.100149, PMID: 34870138
28. Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatol Int. (2019) 13:766–76. doi: 10.1007/s12072-019-09982-z, PMID: 31559605
29. Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. (2018) 7:562. doi: 10.3390/jcm7120562, PMID: 30562976
30. Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, and Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. (2013) 47:280–6. doi: 10.1097/MCG.0b013e31826be328, PMID: 23391869
31. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. (2018) 67:328–57. doi: 10.1002/hep.29367, PMID: 28714183
32. Jiang SY, Yang X, Yang Z, Li JW, Xu MQ, Qu YX, et al. Discovery of an insulin-induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element-binding protein-mediated lipogenesis. Hepatology. (2022) 76:1466–81. doi: 10.1002/hep.32381, PMID: 35102596
33. Mohs A, Otto T, Schneider KM, Peltzer M, Boekschoten M, Holland CH, et al. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. J Hepatol. (2021) 74:638–48. doi: 10.1016/j.jhep.2020.09.037, PMID: 33342543
34. Liu Q, Yu J, Wang L, Tang Y, Zhou Q, Ji S, et al. Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. J Hepatol. (2020) 73:361–70. doi: 10.1016/j.jhep.2020.02.025, PMID: 32135178
35. Zhang Z and Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. (2025) 25:425–444. doi: 10.1038/s41577-024-01112-7, PMID: 39774812
36. Zhang T and Song H. Research Progress on Interferon Gene Stimulating Factors and Type I interferon diseases. Chin J Rheumatol. (2022) 26:396–400. doi: 10.3760/cma.J.c.n141217-20211227-00521
37. González-Navajas JM, Lee J, David M, and Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. (2012) 12:125–35. doi: 10.1038/nri3133, PMID: 22222875
38. Gong J, Gao X, Ge S, Li H, Wang R, and Zhao L. The role of cGAS-STING signalling in metabolic diseases: from signalling networks to targeted intervention. Int J Biol Sci. (2024) 20:152–74. doi: 10.7150/ijbs.84890, PMID: 38164186
39. Xu Q, Xing J, Wang S, Peng H, and Liu Y. The role of the cGAS-STING pathway in metabolic diseases. Heliyon. (2024) 10:e33093. doi: 10.1016/j.heliyon.2024.e33093, PMID: 38988528
40. Odegaard JI and Chawla A. Type 2 responses at the interface between immunity and fat metabolism. Curr Opin Immunol. (2015) 36:67–72. doi: 10.1016/j.coi.2015.07.003, PMID: 26204571
41. Cai Y, Li H, Liu M, Pei Y, Zheng J, Zhou J, et al. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology. (2018) 68:48–61. doi: 10.1002/hep.29777, PMID: 29315766
42. Kobayashi Y, Bustos MA, Hayashi Y, Yu Q, and Hoon D. Interferon-induced factor 16 is essential in metastatic melanoma to maintain STING levels and the immune responses upon IFN-γ response pathway activation. J Immunother Cancer. (2024) 12:e009590. doi: 10.1136/jitc-2024-009590, PMID: 39424359
43. Wong PY, Chan CYK, Xue HDG, Goh CC, Cheu JWS, Tse APW, et al. Cell cycle inhibitors activate the hypoxia-induced DDX41/STING pathway to mediate antitumor immune response in liver cancer. JCI Insight. (2024) 9:e170532. doi: 10.1172/jci.insight.170532, PMID: 39388278
44. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. (2007) 448:501–5. doi: 10.1038/nature06013, PMID: 17618271
45. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature. (2008) 451:725–9. doi: 10.1038/nature06537, PMID: 18256672
46. Cho MG, Kumar RJ, Lin CC, Boyer JA, Shahir JA, Fagan-Solis K, et al. MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis. Nature. (2024) 625:585–92. doi: 10.1038/s41586-023-06889-6, PMID: 38200309
47. Luzwick JW, Dombi E, Boisvert RA, Roy S, Park S, Kunnimalaiyaan S, et al. MRE11-dependent instability in mitochondrial DNA fork protection activates a cGAS immune signaling pathway. Sci Adv. (2021) 7:eabf9441. doi: 10.1126/sciadv.abf9441, PMID: 34910513
48. Kondo T, Kobayashi J, Saitoh T, Maruyama K, Ishii KJ, Barber GN, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A. (2013) 110:2969–74. doi: 10.1073/pnas.1222694110, PMID: 23388631
49. Ferguson BJ, Mansur DS, Peters NE, Ren H, and Smith GL. DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. Elife. (2012) 1:e00047. doi: 10.7554/eLife.00047, PMID: 23251783
50. Unterholzner L and Dunphy G. cGAS-independent STING activation in response to DNA damage. Mol Cell Oncol. (2019) 6:1558682. doi: 10.1080/23723556.2018.1558682, PMID: 31211228
51. Shu C, Li X, and Li P. The mechanism of double-stranded DNA sensing through the cGAS-STING pathway. Cytokine Growth Factor Rev. (2014) 25:641–8. doi: 10.1016/j.cytogfr.2014.06.006, PMID: 25007740
52. Motwani M, Pesiridis S, and Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. (2019) 20:657–74. doi: 10.1038/s41576-019-0151-1, PMID: 31358977
53. Ergun SL, Fernandez D, Weiss TM, and Li L. STING polymer structure reveals mechanisms for activation, hyperactivation, and inhibition. Cell. (2019) 178:290–301. doi: 10.1016/j.cell.2019.05.036, PMID: 31230712
54. Li YX, Cui SF, Meng W, Hu HY, and Wang C. Mitochondrial DNA and cGAS-STING innate immune signaling pathway: latest research progress. Sichuan Da Xue Xue Bao Yi Xue Ban. (2021) 52:387–95. doi: 10.12182/20210560501, PMID: 34018355
55. Xiao Y, Zhao C, Tai Y, Li B, Lan T, Lai E, et al. STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome. Redox Biol. (2023) 62:102691. doi: 10.1016/j.redox.2023.102691, PMID: 37018971
56. Geng Y, Faber KN, de Meijer VE, Blokzijl H, and Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int. (2021) 15:21–35. doi: 10.1007/s12072-020-10121-2, PMID: 33548031
57. Dvorkin S, Cambier S, Volkman HE, and Stetson DB. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity. (2024) 57:718–30. doi: 10.1016/j.immuni.2024.02.019, PMID: 38599167
58. Meng Y, Li X, and Xu H. TFEB links the cGAS-STING pathway to lysosome biogenesis. Trends Cell Biol. (2024) 34:983–5. doi: 10.1016/j.tcb.2024.10.011, PMID: 39547882
59. Wang Z, Chen N, Li Z, Xu G, Zhan X, Tang J, et al. The cytosolic DNA-sensing cGAS-STING pathway in liver diseases. Front Cell Dev Biol. (2021) 9:717610. doi: 10.3389/fcell.2021, PMID: 34386500
60. Motani K, Saito-Tarashima N, Nishino K, Yamauchi S, Minakawa N, and Kosako H. The Golgi-resident protein ACBD3 concentrates STING at ER-Golgi contact sites to drive export from the ER. Cell Rep. (2022) 41:111868. doi: 10.1016/j.celrep.2022.111868, PMID: 36543137
61. Sun L, Wu J, Du F, Chen X, and Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. (2013) 339:786–91. doi: 10.1126/science.1232458, PMID: 23258413
62. Maher JJ. Macrophages steal STING from the infectious disease playbook to promote nonalcoholic fatty liver disease. Gastroenterology. (2018) 155:1687–8. doi: 10.1053/j.gastro.2018.11.009, PMID: 30419212
63. Luo XJ, Li HG, Ma LQ, Zhou J, Guo X, Woo SL, et al. Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice. Gastroenterology. (2018) 155:1971–84. doi: 10.1053/j.gastro.2018.09.010, PMID: 30213555
64. Bai J and Liu F. The cGAS-cGAMP-STING pathway: a molecular link between immunity and metabolism. Diabetes. (2019) 68:1099–108. doi: 10.2337/dbi18-0052, PMID: 31109939
65. Mohlenberg M, Terczynska-Dyla E, Thomsen KL, George J, Eslam M, Grønbæk H, et al. The role of IFN in the development of NAFLD and NASH. Cytokine. (2019) 124:154519. doi: 10.1016/j.cyto.2018.08.013, PMID: 30139548
66. Clare K, Dillon JF, and Brennan PN. Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. J Clin Transl Hepatol. (2022) 10:939–46. doi: 10.14218/JCTH.2022.00067, PMID: 36304513
67. Decout A, Katz JD, Venkatraman S, and Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. (2021) 21:548–69. doi: 10.1038/s41577-021-00524-z, PMID: 33833439
68. Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol. (2021) 18:24–39. doi: 10.1038/s41575-020-00366-5
69. Guillot A and Tacke F. Liver macrophages: Old dogmas and new insights. Hepatol Commun. (2019) 3:730–43. doi: 10.1002/hep4.1356, PMID: 31168508
70. Shen X, Sun C, Cheng Y, Ma D, Sun Y, Lin Y, et al. cGAS Mediates Inflammation by Polarizing Macrophages to M1 Phenotype via the mTORC1 Pathway. J Immunol. (2023) 210:1098–107. doi: 10.4049/jimmunol.2200351, PMID: 36881861
71. Morgantini C, Jager J, Li X, Levi L, Azzimato V, Sulen A, et al. Liver macrophages regulate systemic metabolism through non⁃inflammatory factors. Nat Metab. (2019) 1:445–59. doi: 10.1038/s42255-019-0044-9, PMID: 32694874
72. Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, et al. De-pletion of liver Kupffer cells prevents the development of Diet-induced hepatic steatosis and insulin resistance. Diabetes. (2010) 59:347–57. doi: 10.2337/db09-0016, PMID: 19934001
73. Neyrinck AM, Cani PD, Dewulf EM, De Backer F, Bindels LB, and Delzenne NM. Criti-cal role of Kupffer cells in the management of diet -induced diabetes and obesity. Biochem Biophys Res Commun. (2009) 385:351–6. doi: 10.1016/j.bbrc.2009.05.070, PMID: 19463788
74. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, and Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. (2012) 287:40161–72. doi: 10.1074/jbc.M112.417014, PMID: 23066023
75. Akhmetova K, Balasov M, and Chesnokov I. Drosophila STING protein has a role in lipid metabolism. Elife. (2021) :10:e67358. doi: 10.7554/eLife.67358, PMID: 34467853
76. Passos E, Ascensão A, Martins MJ, and Magalhães J. Endoplasmic reticulum stress response in non-alcoholic steatohepatitis: the possible role of physical exercise. Metabolism. (2015) 64:780–92. doi: 10.1016/j.metabol.2015.02.003, PMID: 25838034
77. Ashraf NU and Sheikh TA. Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res. (2015) 49:1405–18. doi: 10.3109/10715762.2015.1078461, PMID: 26223319
78. Cheng H, Gang X, He G, Liu Y, Wang Y, Zhao X, et al. The molecular mechanisms underlying mitochondria-associated endoplasmic reticulum membrane-induced insulin resistance. Front Endocrinol (Lausanne). (2020) 11:592129. doi: 10.3389/fendo.2020.592129, PMID: 33329397
79. An Y, Geng K, Wang HY, Wan SR, Ma XM, Long Y, et al. Hyperglycemia-induced STING signaling activation leads to aortic endothelial injury in diabetes. Cell Commun Signal. (2023) 21:365. doi: 10.1186/s12964-023-01393-w, PMID: 38129863
80. Geng K, Ma X, Jiang Z, Huang W, Gu J, Wang P, et al. High glucose-induced STING activation inhibits diabetic wound healing through promoting M1 polarization of macrophages. Cell Death Discov. (2023) 9:136. doi: 10.1038/s41420-023-01425-x, PMID: 37100799
81. Liu H, Hu Q, Ren K, Wu P, Wang Y, and Lv C. ALDH2 mitigates LPS-induced cardiac dysfunction, inflammation, and apoptosis through the cGAS/STING pathway. Mol Med. (2023) 29:171. doi: 10.1186/s10020-023-00769-5, PMID: 38124089
82. Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, et al. Gut microbiota and NAFLD: pathogenetic mechanisms, microbiota signatures, and therapeutic interventions. Microorganisms. (2021) 9:957. doi: 10.3390/microorganisms9050957, PMID: 33946843
83. Hernández-Ceballos W, Cordova-Gallardo J, and Mendez-Sanchez N. Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases. J Clin Transl Hepatol. (2021) 9:227–38. doi: 10.14218/JCTH.2020.00131, PMID: 34007805
84. Maslowski KM and Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. (2011) 12:5–9. doi: 10.1038/ni0111-5, PMID: 21169997
85. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. (2014) 505:559–63. doi: 10.1038/nature12820, PMID: 24336217
86. Arias-Jayo N, Abecia L, Alonso-Sáez L, Ramirez-Garcia A, Rodriguez A, and Pardo MA. High-fat diet consumption induces microbiota dysbiosis and intestinal inflammation in zebrafish. Microb Ecol. (2018) 76:1089–101. doi: 10.1007/s00248-018-1198-9, PMID: 29736898
87. Mao Y, Luo W, Zhang L, Wu W, Yuan L, Xu H, et al. STING-IRF3 triggers endothelial inflammation in response to free fatty acid-induced mitochondrial damage in diet-induced obesity. Arterioscler Thromb Vasc Biol. (2017) 37:920–9. doi: 10.1161/ATVBAHA.117.309017, PMID: 28302626
88. Kostovcikova K, Coufal S, Galanova N, Fajstova A, Hudcovic T, Kostovcik M, et al. Diet rich in animal protein promotes pro-inflammatory macrophage response and exacerbates colitis in mice. Front Immunol. (2019) 10:919. doi: 10.3389/fimmu.2019.00919, PMID: 31105710
89. Fajstova A, Galanova N, Coufal S, Malkova J, Kostovcik M, Cermakova M, et al. Diet rich in simple sugars promotes pro-inflammatory response via gut microbiota alteration and TLR4 signaling. Cells. (2020) 9:2701. doi: 10.3390/cells9122701, PMID: 33339337
90. Schulthess J, Pandey S, Capitani M, Rue-Albrecht KC, Arnold I, Franchini F, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity. (2019) 50:432–45. doi: 10.1016/j.immuni.2018.12.018, PMID: 30683619
91. Siddiqui MA and Yamashita M. Toll-like receptor (TLR) signaling enables cyclic GMP-AMP synthase (cGAS) sensing of HIV-1 infection in macrophages. mBio. (2021) 12:e0281721. doi: 10.1128/mBio.02817-21, PMID: 34844429
92. Luo S, Luo R, Lu H, Zhang R, Deng G, Luo H, et al. Activation of cGAS-STING signaling pathway promotes liver fibrosis and hepatic sinusoidal microthrombosis. Int Immunopharmacol. (2023) 125:111132. doi: 10.1016/j.intimp.2023.111132, PMID: 37951190
93. Li Z, Chen B, Dong W, Kong M, Fan Z, Yu L, et al. MKL1 promotes endothelial-to-mesenchymal transition and liver fibrosis by activating TWIST1 transcription. Cell Death Dis. (2019) 10:899. doi: 10.1038/s41419-019-2101-4, PMID: 31776330
94. Guo Q, Furuta K, Islam S, Caporarello N, Kostallari E, Dielis K, et al. Liver sinusoidal endothelial cell expressed vascular cell adhesion molecule 1 promotes liver fibrosis. Front Immunol. (2022) 13:983255. doi: 10.3389/fimmu.2022.983255, PMID: 36091042
95. Su T, Yang Y, Lai S, Jeong J, Jung Y, McConnell M, et al. Single-cell transcriptomics reveals zone-specific alterations of liver sinusoidal endothelial cells in cirrhosis. Cell Mol Gastroenterol Hepatol. (2021) 11:1139–61. doi: 10.1016/j.jcmgh.2020.12.007, PMID: 33340713
96. Chung KW, Dhillon P, Huang S, Sheng X, Shrestha R, Qiu C, et al. Mitochondrial damage and activation of the STING pathway lead to renal inflammation and fibrosis. Cell Metab. (2019) 30:784–799.e5. doi: 10.1016/j.cmet.2019.08.003, PMID: 31474566
97. Luo X, Zhao Y, Luo Y, Lai J, Ji J, Huang J, et al. Cytosolic mtDNA-cGAS-STING axis contributes to sepsis-induced acute kidney injury via activating the NLRP3 inflammasome. Clin Exp Nephrol. (2024) 28:375–90. doi: 10.1007/s10157-023-02448-5, PMID: 38238499
98. Kiapidou S, Liava C, Kalogirou M, Akriviadis E, and Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol. (2020) 19:134–44. doi: 10.1016/j.aohep.2019.07.013, PMID: 31606352
99. Su W, Chen M, Xiao L, Du S, Xue L, Feng R, et al. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease. Front Public Health. (2022) 10:1047794. doi: 10.3389/fpubh.2022.1047794, PMID: 36420005
100. Bai J and Liu F. cGAS–STING signaling and function in metabolism and kidney diseases. J Mol Cell Biol. (2021) 13:728–38. doi: 10.1093/jmcb/mjab066, PMID: 34665236
101. Skopelja-Gardner S, An J, and Elkon KB. Role of the cGAS-STING pathway in systemic and organ-specific diseases. Nat Rev Nephrol. (2022) 18:558–72. doi: 10.1038/s41581-022-00589-6, PMID: 35732833
102. Bai J, Cervantes C, Liu J, He S, Zhou H, Zhang B, et al. DsbA-L prevents obesity-induced inflammation and insulin resistance by suppressing the mtDNA release-activated cGAS-cGAMP-STING pathway. Proc Natl Acad Sci U S A. (2017) 114:12196–201. doi: 10.1073/pnas.1708744114, PMID: 29087318
103. Yang M, Liu Y, Luo SL, Liu CB, Jiang N, Li CR, et al. DsbA-L ameliorates renal aging and renal fibrosis by maintaining mitochondrial homeostasis. Acta Pharmacol Sin. (2024) 45:777–89. doi: 10.1038/s41401-023-01216-1, PMID: 38200148
104. Li X, Pan J, Li H, Li G, Liu X, Liu B, et al. DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nat Commun. (2020) 11:4467. doi: 10.1038/s41467-020-18304-z, PMID: 32948751
105. Liu J, Gong W, and Zhang A. Research progress on the activation mechanism of the CGAS-cGAMP-STING signaling pathway and its role in kidney diseases. Chin J Nephrol. (2021) 37:369–74. doi: 10.3760/cma.j.cn441217-20200916-00054
106. Lv J, Xing C, Chen Y, Bian H, Lv N, Wang Z, et al. The STING in non-alcoholic fatty liver diseases: potential therapeutic targets in inflammation-carcinogenesis pathway. Pharm (Basel). (2022) 15:1241. doi: 10.3390/ph15101241, PMID: 36297353
107. Qiao JT, Cui C, Qing L, et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism. (2018) 81:13–24. doi: 10.1016/j.metabol.2017.09.010, PMID: 29106945
108. Petrasek J, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci U S A. (2013) 110:16544–9. doi: 10.1073/pnas.1308331110, PMID: 24052526
109. Kracht M, Müller-Ladner U, and Schmitz ML. Mutual regulation of metabolic processes and proinflammatory NF-κB signaling. J Allergy Clin Immunol. (2020) 146:694–705. doi: 10.1016/j.jaci.2020.07.027, PMID: 32771559
110. Schmitz ML, Shaban MS, Albert BV, Gökçen A, and Kracht M. The crosstalk of endoplasmic reticulum (ER) stress pathways with NF-κB: complex mechanisms relevant for cancer, inflammation and infection. Biomedicines. (2018) 6:58. doi: 10.3390/biomedicines6020058, PMID: 29772680
111. Hammar EB, Irminger JC, Rickenbach K, Parnaud G, Ribaux P, Bosco D, et al. Activation of NF-kappaB by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells. J Biol Chem. (2005) 280:30630–7. doi: 10.1074/jbc.M502493200, PMID: 15994334
112. Lu H, Lei X, and Zhang Q. Moderate activation of IKK2-NF-kB in unstressed adult mouse liver induces cytoprotective genes and lipogenesis without apparent signs of inflammation or fibrosis. BMC Gastroenterol. (2015) 15:94. doi: 10.1186/s12876-015-0325-z, PMID: 26219821
113. Zhang X, Zhang G, Zhang H, Karin M, Bai H, and Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. (2008) 135:61–73. doi: 10.1016/j.cell.2008.07.043, PMID: 18854155
114. Baker RG, Hayden MS, and Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. (2011) 13:11–22. doi: 10.1016/j.cmet.2010.12.008, PMID: 21195345
115. Heida A, Gruben N, Catrysse L, Koehorst M, Koster M, Kloosterhuis NJ, et al. The hepatocyte IKK: NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis. Mol Metab. (2021) 54:101349. doi: 10.1016/j.molmet.2021.101349, PMID: 34626855
116. Tilg H and Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. (2010) 52:1836–46. doi: 10.1002/hep.24001, PMID: 21038418
117. Liu T, Zhang L, Joo D, and Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. (2017) 2:17023. doi: 10.1038/sigtrans.2017.23, PMID: 29158945
118. Luo K, Chen Y, Fang S, Wang S, Wu Z, and Li H. Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis. Front Endocrinol (Lausanne). (2023) 14:1231520. doi: 10.3389/fendo.2023.1231520, PMID: 37720529
119. Zhang X, He B, Lu J, Bao Q, Wang J, and Yang Y. The crucial roles and research advances of cGAS-STING pathway in liver diseases. Ann Med. (2024) 56:2394588. doi: 10.1080/07853890.2024.2394588, PMID: 39183465
120. Bournique E, Sanchez A, Oh S, Ghazarian D, Mahieu AL, Manjunath L, et al. ATM and IRAK1 orchestrate two distinct mechanisms of NF-κB activation in response to DNA damage. Nat Struct Mol Biol. (2025) 32:740–755. doi: 10.1038/s41594-024-01417-0, PMID: 39753776
121. Feng AC, Thomas BJ, Purbey PK, de Melo FM, Liu X, Daly AE, et al. The transcription factor NF-κB orchestrates nucleosome remodeling during the primary response to Toll-like receptor 4 signaling. Immunity. (2024) 57:462–477.e9. doi: 10.1016/j.immuni.2024.02.004, PMID: 38430908
122. Zhang JN, Dong MM, Cao W, Chen HG, Gu HY, Feng YL, et al. Disruption of DNA-PKcs-mediated cGAS retention on damaged chromatin potentiates DNA damage-inducing agent-induced anti-multiple myeloma activity. Br J Cancer. (2024) 131:430–43. doi: 10.1038/s41416-024-02742-3, PMID: 38877108
123. Cao D, Han X, Fan X, Xu RM, and Zhang X. Structural basis for nucleosome-mediated inhibition of cGAS activity. Cell Res. (2020) 30:1088–97. doi: 10.1038/s41422-020-00422-4, PMID: 33051594
124. Zhang L, Wei X, Wang Z, Liu P, Hou Y, et al. NF-κB activation enhances STING signaling by altering microtubule-mediated STING trafficking. Cell Rep. (2023) 42:112185. doi: 10.1016/j.celrep.2023.112185, PMID: 36857187
125. Liu W, Zhang Chen Z, Yang C, Fan Y, Qiao L, et al. Update on the STING signaling pathway in developing nonalcoholic fatty liver disease. J Clin Transl Hepatol. (2024) 12:91–9. doi: 10.14218/JCTH.2023.00197, PMID: 38250469
126. Ma X, Wu W, Liang W, Takahashi Y, Cai J, and Ma JX. Modulation of cGAS-STING signaling by PPARα in a mouse model of ischemia-induced retinopathy. Proc Natl Acad Sci U S A. (2022) 119:e2208934119. doi: 10.1073/pnas.2208934119, PMID: 36409895
127. He YQ, Zhou CC, Deng JL, Wang L, and Chen WS. Tanreqing inhibits LPS-induced acute lung injury in vivo and in vitro through downregulating STING signaling pathway. Front Pharmacol. (2021) 12:746964. doi: 10.3389/fphar.2021.746964, PMID: 34721036
128. Ma XM, Geng K, Law BY, Wang P, Pu YL, Chen Q, et al. Lipotoxicity-induced mtDNA release promotes diabetic cardiomyopathy by activating the cGAS-STING pathway in obesity-related diabetes. Cell Biol Toxicol. (2023) 39:277–99. doi: 10.1007/s10565-021-09692-z, PMID: 35235096
129. Zang R, Xue L, Zhang M, Peng X, Li X, Du K, et al. Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist. Eur J Med Chem. (2023) 250:115184–4. doi: 10.1016/j.ejmech.2023.115184, PMID: 36758305
130. Pan Y, You Y, Sun L, Sui Q, Liu L, Yuan H, et al. The STING antagonist H-151 ameliorates psoriasis via suppression of STING/NF-κB-mediated inflammation. Br J Pharmacol. (2021) 178:4907–22. doi: 10.1111/bph.15673, PMID: 34460100
131. Butey S, Brown ML, Julson JR, Marayati R, Atigadda VR, Shaikh MG, et al. A novel rexinoid agonist, UAB116, decreases metastatic phenotype in hepatoblastoma by inhibiting the wnt/β-catenin pathway via upregulation of TRIM29. Int J Mol Sci. (2025) 26:3933. doi: 10.3390/ijms26093933, PMID: 40362175
132. Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS, et al. TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun. (2017) 8:945. doi: 10.1038/s41467-017-00101-w, PMID: 29038422
133. Ji S and Wang L. Reduced tripartite motif-containing protein 29 deteriorates the severity of severe acute pancreatitis. Pancreas. (2022) 51:469–75. doi: 10.1097/MPA.0000000000002047, PMID: 35835099
134. Wang J, Lu W, Zhang J, Du Y, Fang M, Zhang A, et al. Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice. Nat Commun. (2024) 15:3481. doi: 10.1038/s41467-024-44745-x, PMID: 38664417
135. Tao Y, Yin S, Liu Y, Li C, Chen Y, Han D, et al. UFL1 promotes antiviral immune response by maintaining STING stability independent of UFMylation. Cell Death Differ. (2023) 30:16–26. doi: 10.1038/s41418-022-01041-9, PMID: 35871231
136. Wang J, Wang L, Lu W, Farhataziz N, Gonzalez A, Xing J, et al. TRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways. Mucosal Immunol. (2025) 18:135–50. doi: 10.1016/j.mucimm.2024.10.004, PMID: 39396665
137. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. (2012) 482:179–85. doi: 10.1038/nature10809, PMID: 22297845
138. Tang C, Wang Q, Shen J, Wang C, Ding H, Wen S, et al. Neuron stem cell NLRP6 sustains hippocampal neurogenesis to resist stress-induced depression. Acta Pharm Sin B. (2023) 13:2017–38. doi: 10.1016/j.apsb.2023.03.010, PMID: 37250149
139. Qiu F, Xiong JP, Deng J, and Xiang XJ. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol. (2015) 8:5053–61., PMID: 26191199
140. Liu C, Huang X, Hou S, Hu B, and Li H. Silencing of tripartite motif (TRIM) 29 inhibits proliferation and invasion and increases chemosensitivity to cisplatin in human lung squamous cancer NCI-H520 cells. Thorac Cancer. (2015) 6:31–7. doi: 10.1111/1759-7714.12130, PMID: 26273332
141. Sun L, Wang D, Chen Z, and Zhu X. TRIM29 knockdown prevented the colon cancer progression through decreasing the ubiquitination levels of KRT5. Open Life Sci. (2023) 18:20220711. doi: 10.1515/biol-2022-0711, PMID: 37671092
142. Yi Q, Zhao Y, Xia R, Wei Q, Chao F, Zhang R, et al. TRIM29 hypermethylation drives esophageal cancer progression via suppression of ZNF750. Cell Death Discov. (2023) 9:191. doi: 10.1038/s41420-023-01491-1, PMID: 37365152
143. Saleh Z, Noroozi M, Vakili ME, Kabelitz D, Nasrollahi H, and Kalantar K. Targeting TRIM29 as a negative regulator of CAR-NK cell effector function to improve antitumor efficacy of these cells: A perspective. Curr Mol Med. (2024) 24:399–403. doi: 10.2174/1566524023666230510101525, PMID: 37218209
144. Yue C, Qian Y, Wang C, Chen J, Wang J, Wang Z, et al. TRIM29 acts as a potential senescence suppressor with epigenetic activation in nasopharyngeal carcinoma. Cancer Sci. (2023) 114:3176–89. doi: 10.1111/cas.15852, PMID: 37248790
145. Han J, Zhang X, Fan ZS, Wang L, Feng L, Zuo J, et al. Prediction value of TRIM29 on immunotherapy in colorectal cancer. J Clin Oncol. (2022) 40:e15533–3. doi: 10.1200/JCO.2022.40.16_suppl.e15533
146. Li G, She FF, Liao CY, Wang ZW, Wang YT, Wu YD, et al. cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis. Cell Death Dis. (2024) 15:742. doi: 10.1038/s41419-024-07138-y, PMID: 39394197
147. Tang Y, Fan S, Peng R, Liu H, Su B, Tu D, et al. TRIM29 reverses lenvatinib resistance in liver cancer cells by ubiquitinating and degrading YBX1 to inhibit the PI3K/AKT pathway. Transl Oncol. (2025) 53:102294. doi: 10.1016/j.tranon.2025.102294, PMID: 39874728
148. Li XJ, Qu JR, Zhang YH, and Liu RP. The dual function of cGAS-STING signaling axis in liver diseases. Acta Pharmacol Sin. (2024) 45:1115–29. doi: 10.1038/s41401-023-01220-5, PMID: 38233527
149. Yu T, Gao M, Yang P, Liu D, Wang D, Song F, et al. Insulin promotes the phenotype transformation of macrophages during wound healing in diabetes through PI3K/Akt and PPAR - γ signal transduction. J Cell Physiol. (2019) 234:4217–31. doi: 10.1002/jcp.27185, PMID: 30132863
150. Bako HY, Ibrahim MA, Isah MS, and Ibrahim S. Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. Life Sci. (2019) 239:117045. doi: 10.1016/j.lfs.2019.117045, PMID: 31730866
151. Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. (2019) 33:1978–95. doi: 10.1038/s41375-019-0379-y, PMID: 30718771
152. Markovich JR, Margarita K, Maksim S, Zolotovskaia M, Koroleva E, Kremenchutckaya K, et al. The role of the metabolism of zinc and manganese ions in human cancerogenesis. Biomedicines. (2022) 10:1072–2. doi: 10.3390/biomedicines10051072, PMID: 35625809
153. Mohammadi S and Khorasani M. Implications of the cGAS-STING pathway in diabetes: Risk factors and therapeutic strategies. Int J Biol Macromol. (2024) 278:134210. doi: 10.1016/j.ijbiomac.2024.134210, PMID: 39069057
154. Chen R, Du J, Zhu H, and Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep. (2021) 3:100324. doi: 10.1016/j.jhepr.2021.100324, PMID: 34381984
155. Chen B, Rao X, Wang X, Luo Z, Wang J, Sheng S, et al. cGAS-STING signaling pathway and liver disease: from basic research to clinical practice. Front Pharmacol. (2021) 12:719644. doi: 10.3389/fphar.2021.719644, PMID: 34483930
156. Pastora LE, Namburu NS, Arora K, Christov PP, and Wilson JT. STING-pathway inhibiting nanoparticles (SPINs) as a platform for treatment of inflammatory diseases. ACS Appl Bio Mater. (2024) 7:4867–78. doi: 10.1021/acsabm.3c01305, PMID: 38563162
Keywords: metabolically associated fatty liver disease, immune signaling pathway, cGAS/STING/NF-κB, pathogenesis, intervention strategy
Citation: Tian R and Li Y (2025) Exploring the pathogenesis of MAFLD from an immunological perspective: from the perspective of the cGAS/STING/NF-κB signaling pathway. Front. Immunol. 16:1674018. doi: 10.3389/fimmu.2025.1674018
Received: 27 July 2025; Accepted: 10 September 2025;
Published: 29 September 2025.
Edited by:
Junji Xing, Houston Methodist Research Institute, United StatesReviewed by:
Niranjan Dodantenna, International Vaccine Centre (VIDO-InterVac), CanadaOmkar Shinde, Sinhgad Dental College and Hospital, India
Copyright © 2025 Tian and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yong Li, TGl5MTk1OEAxNjMuY29t